Business
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4)
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –\nANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. “Since releasing the positive topline results, we have fielded enthusiastic inquiries from health care providers and scientific leaders, so we are eager to share CLEAR Outcomes data in greater detail,” said Sheldon Koenig, Esperion’s president and chief executive officer. “We are honored to kick off the Late Breaking Clinical Trial sessions at ACC.23/WCC and look forward to showcasing the broad cardiovascular risk reduction results that NEXLETOL has demonstrated.” Late Breaking Clinical Trial PresentationTitle: CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular RiskLocation: Main Tent (Great Hall)Date & Time: 3/4/2022, 9:30 – 9:42 AM CSTSpeaker: Steven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic Industry Expert TheatreTitle: A Next Step in LDL-C–Lowering Therapy: Oral Nonstatin TherapiesLocation: Industry Expert Theatre #2, Location 2455Date & Time: 3/5/2022, 11:15 AM – 12:15 PM CSTSpeaker: Kausik Ray, BSc (hons), MBChB, FRCP (Lon), FRCP (Ed), MD, MPhil (Cantab), FACC, FESC, FAHA CLEAR Outcomes Late Breaking Clinical Trial Deep Dive – Session 408Title: Bempedoic Acid And Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular RiskLocation: Main Tent (Great Hall)Date & Time: 3/5/2022, 2:00 – 2:05 PM CSTSpeaker: Steven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic INDICATIONNEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.Limitations of Use: The effect of NEXLETOL on cardiovascular morbidity and mortality has not b...